Transforming growth factor-Β and diabetic nephropathy

Journal of Organ Dysfunction

Volumn 5, Issue 3, 2009, Pages 130-139

  Wolf, Gunter ^a   Ziyadeh, Fuad N ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Albuminuria; Angiotensin II; Diabetic nephropathy; Glomerulopathy; Smad; Thrombospondin; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

DIABETIC NEPHROPATHY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; IMMUNE RESPONSE; KIDNEY FAILURE; KIDNEY FIBROSIS; MESENCHYME CELL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 70849101215     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.1080/17471060701342550     Document Type: Review

References (92)

1. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006;/116:/288-96.
2. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;/112:/1776-84.
3. Sharma K, Ziyadeh FN. The emerging role of transforming growth factor-b in kidney diseases. Am J Physiol 1994;/266:/ F829-42.
4. Border WA, Noble NA. Cytokines in kidney disease: The role of transforming growth factor-b. Am J Kidney Dis 1993;/22:/ 105-113
5. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor b1. Nature 1990;/346:/ 371-374
6. Ziyadeh FN. Mediators of diabetic renal disease: The case for TGF-b as the major mediator. J Am Soc Nephrol 2004;/ 15(Suppl 1):/S55-7.
7. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 2006;/104:/ e129-34.
8. Mauviel A. Transforming growth factor-beta: A key mediator of fibrosis. Methods Mol Med 2005;/117:/69-80.
9. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 2005;/19:/2783-810.
10. Yokoi H, Sugawara A, Mukoyama M, Mori K, Makino H, Suganami T, et al. Role of connective tissue growth factor in profibrotic action of transforming growth factor-b: A potential target for preventing fibrosis. Am J Kidney Dis 2001;/ 38(Suppl 1):/S134-8.
11. Galkina E, Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 2006;/17:/368-77.
12. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-b regulation of immune responses. Annu Rev Immunol 2006;/24:/99-146.
13. Grainger DJ. Transforming growth factor b and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;/24:/399-404.
14. Wolf G, Ziyadeh FN.Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999;/56:/393-405. (Pubitemid 29353136)
15. Monkawa T, Hiromura K, Wolf G, Shankland SJ. Transforming growth factor-b requires the cyclin-dependent kinaseinhibitors p21 and p27 to induce mesangial cell hypertrophy. J Am Soc Nephrol 2002;/13:/1172-8.
16. Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RA. TGF-b stimulates mesangial cell proliferation in culture: Role of PDGF beta-receptor expression. Am J Physiol 1993;/264:/F199-205.
17. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-b superfamily signaling. FASEB J 1999;/ 13:/2105-24.
18. Schultz-Cherry S, Murphy-Ullrich JE. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J Cell Biol 1993;/122:/923-32.
19. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase- 9 proteolytically activates TGF-b and promotes tumor invasion and angiogenesis. Genes Dev 2000;/14:/ 163-176
20. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992;/360:/361-4.
21. Wells RG, Yankelev H, Lin HY, Lodish HF. Biosynthesis of the type I and type II TGF-b receptors*implications for complex formation. J Biol Chem 1997;/272:/11444-51.
22. Massagué J, Chen YG. Controlling TGF-b signaling. Genes Dev 2000;/14:/627-44.
23. Wolf G, Ziyadeh FN, Stahl RAK. Angiotensin II stimulates expression of transforming growth factor-b receptor type II in cultured mouse proximal tubular cells. JMol Med 1999;/77:/ 556-564
24. McCaffrey TA, Du B, Consigli S, Szabo P, Bray PJ, Hartner L, et al. Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restonic vascular cells. J Clin Invest 1997;/100:/2182-8.
25. Poncelet AC, de Caestecker MP, Schnaper HW. The transforming growth factor-b/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int 1999;/56:/ 1354-1365
26. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, et al. Transforming growth factor-beta protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;/68:/154-63.
27. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994;/93:/536-42.
28. Rocco MV, Chen Y, Goldfarb S, Ziyadeh FN. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 1992;/41:/107-14.
29. Waltenberger J, Miyazono K, Funa K, Wanders A, Fellstrom B, Heldin CH. Transforming growth factor-beta and organ transplantation. Transplant Proc 1993;/25:/2038-40.
30. Sugiura T, Yamauchi A, Kitamura H, Matsusoka Y, Horio M, Imai E, et al. Effects of hypertonic stress on transforming growth factor-b activity in normal rat kidney cells. Kidney Int 1998;/53:/1654-60.
31. Wolf G, Panzer U, Stahl RAK. Regulatory peptides and their antagonists in nephropathies. Curr Opin Nephrol Hypertens 2000;/9:/233-9.
32. Tsuchida K, Cronin B, Sharma K. Novel aspects of transforming growth factor-beta in diabetic kidney disease. Nephron 2002;/92:/7-21.
33. Ziyadeh FN. Evidence for the involvement of transforming growth factor-b in the pathogenesis of diabetic kidney disease: Are Koch's postulates fulfilled? Curr Pract Med 1998;/1:/87-9.
34. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN. High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-b. Kidney Int 1992;/42:/647-56.
35. Yang C-W, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994;/91:/9436-40.
36. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN. Angiotensin IIinduced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factorb. J Clin Invest 1993;/92:/1366-72.
37. Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, Patterson D, et al. Cyclic stretching force selectively upregulates transforming growth factor-b isoforms in cultured rat mesangial cells. Am J Pathol 1996;/148:/1915-23.
38. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, et al. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993;/42:/450-6. (Pubitemid 23066522)
39. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993;/90:/1814-8.
40. Bollineni JS, Reddi AS. Transforming growth factor-b1 enhances glomerular collagen synthesis in diabetic rats. Diabetes 1993;/42:/1673-7.
41. Sharma K, Ziyadeh FN. Renal hypertrophy is associated with upregulation of TGF-b1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994;/267:/F1094-101.
42. Hill C, Flyvbjerg A, Gronbaek H, Petrik J, Hill DJ, Thomas CR, et al. The renal expression of transforming growth factorb isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000;/141:/1196-208.
43. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN. Increased glomerular and tubular expression of transforming growth factor-b1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001;/158:/1653-63.
44. Chen S, Jim B, Ziyadeh FN. Diabetic nephropathy and transforming growth factor-beta: Transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol 2003;/23:/532-43.
45. Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin Nephrol 1997;/17:/80-92.
46. Kondo S, Kagami S, Urushihara M, Kitamura A, Shimizu M, Strutz F, et al. Transforming growth factor-beta1 stimulates collagen matrix remodeling through increased adhesive and contractive potential by human renal fibroblasts. Biochim Biophys Acta 2004;/1693:/91-100.
47. Wolf G, Schroder R, Ziyadeh FN, Thaiss F, Zahner G, Stahl RA. High glucose stimulates expression of p27Kip1 in cultured mouse mesangial cells: Relationship to hypertrophy. Am J Physiol 1997;/273:/F348-56.
48. Mahimainathan L, Das F, Venkatesan B, Choudhury GG. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006;/55:/2115-25.
49. Inoki K, Haneda M, Maeda S, Koya D, Kikkawa R. TGF-b1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int 1999;/55:/1704-12.
50. Mogyorosi A, Ziyadeh FN. GLUT1 and TGF-b: The link between hyperglycaemia and diabetic nephropathy. Nephrol Dial Transplant 1999;/14:/2827-9.
51. Lee TS, Saltsman KA, Ohashi H, King GL. Activation of protein kinase C by elevation of glucose concentration: Proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A 1989;/86:/ 5141-5145
52. Heilig CW, Concepcion LA, Riser BL, Freytag SO, Zhu M, Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest 1995;/96:/1802-14.
53. Henry DN, Busik JV, Brosius FC, Heilig CW. Glucose transporters control gene expression of aldose reductase, PKC a, and GLUT1 in mesangial cells in vitro. Am J Physiol 1999;/277:/F97-104.
54. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-b by anti-TGF-b antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;/45:/522-30.
55. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-b antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000;/97:/8015-20.
56. Isono M, Mogyorosi A, Han DC, Hoffman BB, Ziyadeh FN. Stimulation of TGF-b type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol 2000;/278:/F830-8.
57. Wolf G, Shankland SJ. Cell cycle control in glomerular disease. Prog Cell Cycle Res 2003;/5:/71-9.
58. Wolf G, Zahner G, Schroeder R, Stahl R. Transforming growth factor beta mediates the angiotensin II induced stimulation of collagen type IV synthesis in cultured murine proximal tubular cells. Nephrol Dial Transplant 1996;/11:/ 263-269
59. Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-b1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol 2000;/278:/F628-34.
60. Abbate M, Zoja C, Morigi M, Rottoli D, Angioletti S, Tomasoni S, et al. Transforming growth factor-beta1 is upregulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am J Pathol 2002;/161:/2179-93.
61. Gilbert RE, Cox A,Wu LL, Allen TJ, Hulthen UL, Jerums G, et al. Expression of transforming growth factor-b1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: Effects of ACE inhibition. Diabetes 1998;/47:/ 414-422
62. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, Kouahou M, Han DC, Kalluri R, et al. Effects of high glucose and TGF-b1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002;/62:/ 901-913
63. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: Podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;/54:/1626-34.
64. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;/162:/1123-37.
65. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR- 2 in experimental diabetes. Diabetes 1999;/48:/2229-39.
66. Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, Mundel P, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen a5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003;/14:/3178-87.
67. Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP. TGF-b concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005;/16:/3211-21.
68. Dallas SL, Miyazono K, Skerry TM, Mundy GR, Bonewald LF. Dual role for the latent transforming growth factor-b binding protein in storage of latent TGF-b in the extracellular matrix and as a structural matrix protein. J Cell Biol 1995;/ 131:/539-49.
69. Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-b-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002;/296:/ 1356-1365
70. Furuse Y, Hashimoto N, Maekawa M, Toyama Y, Nakao A, Iwamoto I, et al. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats. Nephron Exp Nephrol 2004;/98:/e100-8.
71. Schiffer M, Schiffer LE, Gupta A, Shaw AS, Roberts IS, Mundel P, et al. Inhibitory smads and TGF-b signaling in glomerular cells. J Am Soc Nephrol 2002;/13:/2657-66.
72. Wahab NA, Weston BS, Mason RM. Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005;/307:/305-14.
73. Cordenonsi M, Montagner M, Adorno M, Zacchigna L, Martello G, Mamidi A, et al. Integration of TGF-b and Ras/ MAPK signaling through p53 phosphorylation. Science 2007;/ 315:/840-3.
74. Schiffer M, Mundel P, Shaw AS, Böttinger EP. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-b-induced apoptosis. J Biol Chem 2004;/279:/37004-12.
75. Wu DT, Bitzer M, Ju W, Mundel P, Bottinger EP. TGF-b concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 2005;/16:/3211-21.
76. Li Y, Yang J, Luo JH, Dedhar S, Liu Y. Tubular epithelial cell dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. J Am Soc Nephrol 2007;/18:/449-60.
77. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, et al. Transforming growth factor-b protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993;/68:/154-63.
78. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, et al. Expression of transforming growth factor-b isoforms in human glomerular diseases. Kidney Int 1996;/49:/ 461-469
79. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, et al. Quantification of glomerular TGF-b1 mRNA in patients with diabetes mellitus. Kidney Int 1996;/49:/1120-6.
80. Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, et al. Increased renal production of transforming growth factor-b1 in patients with type II diabetes. Diabetes 1997;/46:/854-9.
81. Tsakas S, Goumenos DS. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 2006;/26:/186-93.
82. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth factor-b1 correlates with longterm renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;/34:/818-23.
83. Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD. Circulating and urinary transforming growth factor b1, Amadori albumin, and complications of type 1 diabetes: The EURODIAB prospective complications study. Diabetes Care 2002;/25:/2320-7.
84. Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, et al. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-b in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 2006;/21:/683-9.
85. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;/18:/16-28.
86. Susztak K, Raff AC, Schiffer M, Böttinger EP. Glucoseinduced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006;/55:/225-33.
87. Iglesias-de la Cruz MC, Ruiz-Torres P, Alcami J, Diez- Marques L, Ortega-Velazquez R, Chen S, et al. Hydrogen peroxide increases extracellular matrix mRNA through TGFb in human mesangial cells. Kidney Int 2001;/59:/87-95.
88. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB. Role of high glucose-induced nuclear factor-kB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 2002;/13:/894-902.
89. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: New targets for antifibrotic therapy? Matrix Biol 2002;/21:/473-82.
90. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the TGF-b pathway. Kidney Int 2006;/70:/ 1914-1919
91. Scaglione R, Argano C, Corrao S, Di Chiara T, Licata A, Licata G. Transforming growth factor b1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: A 24-week randomized controlled trial. J Hypertens 2005;/23:/654-7.
92. Kulkarni AB, Karlsson S. Transforming growth factor-beta 1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993;/143:/3-9.